PATENT

In a method for detecting the presence or abs- ence of a specific restriction site in a nucleic acid sequence an oligonucleotide probe comple- mentary to one strand of the nucleic acid sequence spanning said restriction site is syn- thesized. The probe is labeled at the end nearer the restriction site. The nucleic acid is hybridized to the probe and a blocking oligomer may be ad- ded, if necessary, to prevent non-specific binding of the probe. Subsequent digestion with a restric- tion enzyme cleaves those oligomers that have hybridized to the nucleic acid and reformed the restriction site. The resulting cut and uncut labeled oligomers are separated and detected based on the type of probe label. The described method may be used to detect sickle cell anemia.

4683195

P R O C E S S F O R A M P L I F Y I N G , D E T E C T I N G , A N D / O R - C L O N I N G

N U C L E I C A C I D S E Q U E N C E S

Kary Mullis, Henry Erlich, Norma Arnheim, Glenn T Horn, Randall Saiki, Stephen Scharf as- signed to Cetus Corporation

The present invention is directed to a process for amplifying and detecting any target nucleic acid sequence contained in a nucleic acid or mixture thereof. The process comprises treating separate complementary strands of the nucleic acid with a molar excess of two oligonucleotide primers, ex- tending the primers to form complementary primer extension products which act as tem- plates for synthesizing the desired nucleic acid sequence, and detecting the sequence so am- plified. The steps of the reaction may be carried out stepwise or simultaneously and can be repeated as often as desired. In addition, a specific nucleic acid sequence may be cloned into a vector by using primers to amplify the sequence, which contain restriction sites on their non-complementary ends, and a nucleic acid fragment may be prepared from an existing shor- ter fragment using the amplification process.

4683196

M E T H O D A N D M A T E R I A L S F O R T H E I D E N T I F I C A T I O N O F L I P O P O L Y S A C C H A R I D E

P R O D U C I N G M I C R O O R G A N I S M S

Charles A McLaughlin assigned to Meru lnc

The subject invention provides a means for the immunological detection of an entire class of

ABSTRACTS 313

microorganisms in clinical samples. The detec- tion is accomplished by reaction of the clinical sample iwth a class-specific immunological rea- gent. This reagent is an antiserum either mono- clonal or polyclonal in nature, and the detection is based upon reaction of the antiserum with an antigenic determinant which is shared among all members of the detectable class of micro- organisms. The presence of the resulting immunological reaction product (e.g. the antigen-antibody complex) may be detected by well-known immunological detection-systems.

4 ~ 3 1 ~

I N T E R L E U K I N - 2 D E P E N D E N T C Y T O T O X I C T - C E L L C L O N E S

Michae Palladino assigned to Sloan-Kettering Institute for Cancer Research

interleukin-2 dependent cytotoxic cultured T- cell lines are found to produce £60. + 6 2 , and +65 + 0 interferon, as well as interleukin-2, when stimulated by mitogenic or antigenic a- gents.

4683200

M O N O C L O N A L A N T I B O D Y T O H U M A N C A N C E R A N T I G E N A N D

M E T H O D F O R P R O D U C I N G S A M E

Setsuo Hirohashi, Yukio Shimosato, Masahik Watanabe, Chiyoda ku, Tokyo, Japan assigned to Hirohashi Setsuo; Shimosato Yukio; Watanabe Masahik; Nippon Kayaku Kabushiki Kais

Disclosed herein is a monoclonal antibody of the IgM class which reacts with a glycoprotein anti- gen having a molecular weight by gel filtration of 1.000,000 or higher, the antigenic determinant to be recognized being a sugar chain with a sialic acid residue at the end thereof. The monoclonal antibody has the following characteristics: (1) a reactivity with human cancers of stomach, large intestine, pancreas, breast, lung, biliary duct, uterus and esophagus: (2) a reactivity with nor- mal human submaxillary gland, proximal renal tubule, bronchial gland, squamous epithelial corneum, pancreatic Langerhans£3 + 0 islands, liver cell membrane and duodenal gland; (3) a reactivity with human intestinal metaplastic gastric mucosa; and (4) a non-reactivity with normal human prostate gland, biliary duct and